Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport

No abstract is available for this paper.

• Publication year

  2001

• Venue

  AIDS (London)

• Publication date

  2001-04-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00002030-200104130-00002PMID 11371681
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro.

  2001cited by this paper
• May the Drug Transporter P Glycoprotein Affect the Antiviral Activity of Human Immunodeficiency Virus Type 1 Proteinase Inhibitors?

  2000cited by this paper
• Kinetics of Antiviral Activity and Intracellular Pharmacokinetics of Human Immunodeficiency Virus Type 1 Protease Inhibitors in Tissue Culture

  1999cited by this paper
• Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study.

  1999cited by this paper
• Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients : a prospective cohort study

  1999cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.

  1998cited by this paper
• The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

  1998cited by this paper
• HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

  1998cited by this paper
• Intracellular expression of P-170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients.

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

  1998cited by this paper
• Human Immunodeficiency Virus Protease Inhibitors Serve as Substrates for Multidrug Transporter Proteins MDR1 and MRP1 but Retain Antiviral Efficacy in Cell Lines Expressing These Transporters

  1998cited by this paper
• Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells.

  1998cited by this paper
• Expression of multidrug‐resistance‐associated protein (MRP) and chemosensitivity in human gastric cancer

  1996cited by this paper
• Abnormal Expression of a 170-Kilodalton P-Glycoprotein Encoded by MDR1 Gene, a Metabolically Active Efflux Pump, in CD4+ and CD8+ T Cells from Patients with Human Immunodeficiency Virus Type 1 Infection

  1996cited by this paper
• P-170 glycoprotein (P-170) is involved in the impairment of natural killer cell-mediated cytotoxicity in HIV+ patients.

  1995cited by this paper
• Transmembrane P-Glycoprotein (P-gp/P-170) in HIV Infection: Analysis of Lymphocyte Surface Expression and Drug-Unrelated Function

  1995cited by this paper
• Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line.

  1995cited by this paper
• Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells.

  1994cited by this paper
• Barrier properties of testis microvessels.

  1993cited by this paper
• Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line.

  1992cited by this paper
• Multidrug resistance activity in human lymphocytes.

  1991cited by this paper
• Human immunodeficiency virus I-induced expression of P-glycoprotein.

  1990cited by this paper
• Expression of Multidrug Resistance Gene in Human Cancers

  1989influential reference
• Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.

  1989cited by this paper

• Nelfinavir and Its Active Metabolite M8 Are Partial Agonists and Competitive Antagonists of the Human Pregnane X Receptor

  2021cites this paper
• In vivo modulation of cervicovaginal drug transporters and tissue distribution by film-released tenofovir and darunavir for topical prevention of HIV-1.

  2020cites this paper
• Interactions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: Effect on transplacental disposition in rats.

  2018cites this paper
• A Versatile Method to Determine the Cellular Bioavailability of Small-Molecule Inhibitors

  2017cites this paper
• Intracellular accumulation of Praziquantel in T lymphoblastoid cell lines, CEM (parental) and CEMvbl(P-gp-overexpressing)

  2016influential citation
• Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC-MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a potential drug-drug interaction.

  2016influential citation
• Pharmacogenetics of Respiratory Disease

  2016cites this paper
• Pharmacogenetics and Metabolic Disease

  2016cites this paper
• Transporters for Antiretroviral Drugs in Colorectal CD4+ T Cells and Circulating α4β7 Integrin CD4+ T Cells: Implications for HIV Microbicides.

  2016cites this paper
• Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

  2015cites this paper
• The role of therapeutic drug monitoring and pharmacogenetic testing in the management of HIV infection: a review.

  2015cites this paper
• Gene expression modulation and the molecular mechanisms involved in Nelfinavir resistance in Leishmania donovani axenic amastigotes

  2013cites this paper
• The Antiretroviral Protease Inhibitor Ritonavir Accelerates Glutathione Export from Cultured Primary Astrocytes

  2013cites this paper
• The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition

  2012influential citation
• Expression and induction by dexamethasone of ABC transporters and nuclear receptors in a human T-lymphocyte cell line

  2012cites this paper
• The cellular pharmacokinetics of HIV protease inhibitors: current knowledge and future perspectives.

  2012cites this paper
• A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.

  2011cites this paper
• The Effect of Polymorphisms in Candidate Genes on the Long-Term Risk of Lipodystrophy and Dyslipidemia in HIV-Infected White Patients Starting Antiretroviral Therapy

  2011cites this paper
• Mechanisms of Drug Interactions II: Transport Proteins

  2011cites this paper
• Rôle de la pharmacogénétique dans le métabolisme et le transport des antirétroviraux

  2011cites this paper
• Development of Therapeutic Agents: The Maternal–Fetal Perspective

  2011cites this paper
• Nelfinavir, an HIV-1 Protease Inhibitor, Induces Oxidative Stress–Mediated, Caspase-Independent Apoptosis in Leishmania Amastigotes

  2010cites this paper
• ABC transporters in human lymphocytes: expression, activity and role, modulating factors and consequences for antiretroviral therapies

  2010cites this paper
• Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines.

  2010cites this paper
• Identification of a Potential Pharmacological Sanctuary for HIV Type 1 in a Fraction of CD4+ Primary Cells

  2010cites this paper
• Accumulation of Drugs in Tissues

  2010cites this paper
• The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters.

  2010cites this paper
• The accumulation and metabolism of zidovudine in 3T3‐F442A pre‐adipocytes

  2010cites this paper
• Intact Lipid Rafts Regulate HIV-1 Tat Protein-Induced Activation of the Rho Signaling and Upregulation of P-Glycoprotein in Brain Endothelial Cells

  2010cites this paper
• Modulation of endocrine and transport functions in human trophoblasts by saquinavir and nelfinavir.

  2010cites this paper
• Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy.

  2010cites this paper
• Lack of P-glycoprotein induction by rifampicin and phenobarbital in human lymphocytes.

  2010cites this paper
• Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors

  2009cites this paper
• Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC.

  2009cites this paper
• FACTORS INFLUENCING PLACENTAL TRANSFER OF LOPINAVIR: BINDING, UPTAKE AND EFFLUX

  2009influential citation
• Monitorização das concentrações plasmáticas de Efavirenz: critérios de aplicabilidade à prática clínica e efeitos do fármaco a longo termo

  2009cites this paper
• High Levels of P‐Glycoprotein Activity in Human Lymphocytes in the First 6 Months of Life

  2009cites this paper
• Pharmacogenomics of CYP3A: considerations for HIV treatment.

  2009cites this paper
• Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors.

  2008cites this paper
• Methods to measure the intracellular concentration of unlabeled compounds within cultured cells using liquid chromatography/tandem mass spectrometry.

  2008cites this paper
• [P-glycoprotein and human immunodeficiency virus infection].

  2008cites this paper
• Glucoproteína P e infección por el virus de la inmunodeficiencia humana

  2008cites this paper
• Rôle de la P-glycoprotéine, un transporteur ABC, sur la distribution cardiaque et tissulaire de la dompéridone et répercussions possibles sur l'intervalle QT

  2008cites this paper
• HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein

  2007cites this paper
• Direct Effect of Human Immunodeficiency Virus Protease Inhibitors on Neutrophil Function and Apoptosis via Calpain Inhibition

  2007cites this paper
• Role of ATP-binding cassette transporters in drug distribution to the heart and protection from toxic compounds

  2007influential citation
• Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.

  2007cites this paper
• Les métalloprotéases matricielles 2 et 9 et la différenciation des cellules progénitrices du tissu adipeux humain

  2007cites this paper
• Transporter-mediated uptake into cellular compartments

  2007cites this paper
• Intracellular Efavirenz Levels in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Individuals

  2007cites this paper
• Inhibition of Human Preadipocyte Proteasomal Activity by HIV Protease Inhibitors or Specific Inhibitor Lactacystin Leads to a Defect in Adipogenesis, Which Involves Matrix Metalloproteinase-9

  2007cites this paper
• Expression of Adenosine Triphosphate-Binding Cassette (ABC) Drug Transporters in Peripheral Blood Cells

  2007cites this paper
• Mitoxantrone permeability in MDCKII cells is influenced by active influx transport.

  2007cites this paper
• Antiviral Activity of HIV Type 1 Protease Inhibitors Nelfinavir and Indinavir in Vivo Is Not Influenced by P-Glycoprotein Activity on CD4+ T Cells

  2007cites this paper
• [Preventing the cardiotoxic effects of anthracyclins. From basic concepts to clinical data].

  2006cites this paper
• Multidrug Resistance-Associated Proteins: Expression and Function in the Central Nervous System

  2006cites this paper
• Boosting protease inhibitors with low-dose ritonavir - unravelling the mystery

  2006cites this paper
• The ATP-Binding Cassette Transporters and Their Implication in Drug Disposition: A Special Look at the Heart

  2006cites this paper
• Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.

  2006cites this paper
• Designing pregnancy centered medications: drugs which do not cross the human placenta.

  2006influential citation
• Are Plasma Levels Valid Surrogates for Cellular Concentrations of Antiretroviral Drugs in HIV-infected Patients?

  2006cites this paper
• Quantitative Assessment of HIV-1 Protease Inhibitor Interactions with Drug Efflux Transporters in the Blood–Brain Barrier

  2005cites this paper
• Mechanisms of Drug Interactions II

  2005cites this paper
• The implications of P‐glycoprotein in HIV: friend or foe?

  2005cites this paper
• Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP

  2005cites this paper
• In Vitro Synergy and Enhanced Murine Brain Penetration of Saquinavir Coadministered with Mefloquine

  2005cites this paper
• Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity.

  2005cites this paper
• Early absorption and distribution analysis of antitumor and anti-AIDS drugs: lipid membrane and plasma protein interactions.

  2005cites this paper
• Renal tubular transporters and antiviral drugs: an update

  2005cites this paper
• Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry.

  2005cites this paper
• P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy.

  2005cites this paper
• HIV‐Tat protein induces P‐glycoprotein expression in brain microvascular endothelial cells

  2005cites this paper
• Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo

  2005cites this paper
• MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells

  2005cites this paper
• Multidrug resistance protein 1-mediated transport of saquinavir by microglia

  2004cites this paper
• Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients

  2004cites this paper
• P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy

  2004cites this paper
• The Plasma and Intracellular Steady-State Pharmacokinetics of Lopinavir/Ritonavir in HIV-1-Infected Patients

  2004cites this paper
• The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability.

  2004cites this paper
• P-glycoprotein expression affects the intracellular concentration and antiviral activity of the protease inhibitor saquinavir in a T cell line.

  2004cites this paper
• Transport of HIV Protease Inhibitors Through the Blood-Brain Barrier and Interactions With the Efflux Proteins, P-Glycoprotein and Multidrug Resistance Proteins

  2004cites this paper
• Sensitive Enzyme Immunoassay for Measuring Plasma and Intracellular Nevirapine Levels in Human Immunodeficiency Virus-Infected Patients

  2004cites this paper
• The intracellular pharmacology of antiretroviral protease inhibitors.

  2004cites this paper
• Intracellular Accumulation of Nelfinavir and Its Relationship to P-Glycoprotein Expression and Function in HIV-Infected Patients

  2004cites this paper
• Intracellular and Plasma Pharmacokinetics of Nelfinavir and M8 in HIV-Infected Patients: Relationship with P-Glycoprotein Expression

  2004cites this paper
• An enzyme immunoassay for the quantification of plasma and intracellular lopinavir in HIV-infected patients.

  2004cites this paper
• Pharmacogenomics of MDR and MRP subfamilies.

  2004cites this paper
• THE TRANSPORT AND MODULATION OF HIV PROTEASE INHIBITORS INTO THE RAT CENTRAL NERVOUS SYSTEM AND MILK

  2004cites this paper
• In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins.

  2004cites this paper
• Pharmacogenomics of HIV.

  2004cites this paper
• A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets.

  2003cites this paper
• The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration.

  2003cites this paper
• HIV DNA two long terminal repeat circles : observations and interpretations

  2003cites this paper
• Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEMVBL, CEME1000, MDCKIIMRP1 and MDCKIIMRP2 cell lines

  2003cites this paper
• The mechanisms that control intracellular penetration of the HIV protease inhibitors.

  2003cites this paper
• Protein Binding in Antiretroviral Therapies

  2003cites this paper
• Saquinavir induces stable and functional expression of the multidrug transporter P‐glycoprotein in human CD4 T‐lymphoblastoid CEMrev cells

  2003cites this paper
• Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM(VBL), CEM(E1000), MDCKII(MRP1) and MDCKII(MRP2) cell lines.

  2003cites this paper
• Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

  2003cites this paper
• Implications of T‐Cell P‐Glycoprotein Activity During HIV‐1 Infection and Its Therapy

  2003cites this paper